The Delaware Court of Chancery has dismissed a lawsuit filed by Corcept Therapeutics Inc. against Optime Care, Inc., and transferred the case to the Superior Court. This decision, made on November 20, 2026, affects the business relationship between the two companies, which has been strained over a contract dispute regarding specialty pharmacy services.
Corcept, a biopharmaceutical company known for its drug Korlym, sought specific performance and damages from Optime for alleged breaches of their Distribution Services Agreement. The court’s ruling indicates that Corcept's claims are more suited for a court of law rather than equity, as the primary issues now involve monetary damages.
Background
The parties involved in this case are Corcept Therapeutics Inc., a company that develops Korlym for a rare endocrine disorder, and Optime Care, Inc., a specialty pharmacy that provided services to Corcept. Their relationship began in 2017 under a Distribution Services Agreement, which was amended multiple times over the years.
As patient demand for Korlym increased, Corcept expressed concerns regarding Optime's ability to meet this demand. In June 2025, Corcept exercised its right under the agreement to seek additional specialty pharmacy partners, which led to Optime's assertion that Corcept had breached the agreement. This prompted Corcept to file a lawsuit on October 30, 2025, seeking specific performance and damages for breach of contract and tortious interference.
The Ruling
The court ruled in favor of Optime by granting its motion to dismiss the complaint under Rule 12(b)(1) for lack of subject matter jurisdiction. The court found that Corcept's claims for specific performance were moot since Optime had already fulfilled its obligations related to the transition of patients to a successor pharmacy.
The court stated, "Corcept acknowledges that the transition is complete and identifies nothing left for this court to compel Optime to do. Count VII is thus long moot."
As a result, the court did not consider the other motions to dismiss filed by Optime and its parent company, AscellaHealth. The ruling indicated that Corcept's remaining claims, primarily seeking monetary damages, should be addressed in a court of law.
Impact
This ruling is significant as it clarifies the jurisdictional boundaries of the Delaware Court of Chancery. The court emphasized that it only has jurisdiction over equitable claims, and once those claims are resolved or become moot, it is less inclined to retain jurisdiction over purely legal claims. This decision may influence how similar cases are handled in the future, particularly regarding the distinction between equitable and legal claims.
Corcept's situation illustrates the complexities of business agreements and the importance of understanding the legal frameworks that govern them. The transfer to the Superior Court means that Corcept will need to file a new complaint to pursue its remaining claims.
What's Next
Corcept can appeal this decision, but it will first need to file a complaint in the Superior Court within 60 days to continue pursuing its claims against Optime. The court filing will require Corcept to address the costs incurred in the Court of Chancery as part of the transition to the new court.
Read Next
Court vacates ruling in Promier Products false advertising case
Court affirms insurance coverage for United Rentals claims
Ohio Court Rules on Golf Cart Rental Fee Dispute
Court rules against Mercuria Energy in arbitration dispute
Ohio Court of Appeals vacates ruling on transit union dispute
Florida court affirms ruling in case against Porsche Latin America










